The Primary Aldosteronism Foundation announced the creation of a multi-stakeholder alliance to drive diagnosis and treatment of primary aldosteronism, a common cause of hypertension.
The initiative will facilitate the design and implementation of interventions to advance standards of care for primary aldosteronism, a highly prevalent adrenal disease and common cause of hypertension. Primary aldosteronism is neither diagnosed nor treated 95% of the time despite causing significant cardiovascular and renal damage along with systemic inflammation.
“The Alliance was formed to highlight the unmet medical needs of millions of patients,” says Marianne Leenaerts, co-founder and co-director of the Foundation. “For the first time since the discovery of the disease over 60 years ago, collaborative work will drive actions to remediate this major public health issue by addressing the factors preventing timely and adequate provision of care.”
This step precedes a much-anticipated paradigm shift in the medical treatment of primary aldosteronism with the advent of aldosterone synthase inhibitors, a new class of drugs that, for the very first time, will enable the lowering of aldosterone.
Founding members of the Alliance include U.S. medical societies and stakeholders involved in care delivery, clinical research, and public health. Consensus has emerged to begin work by focusing on primary and specialized care, furthering the research agenda, and improving current guidelines. The initiative looks to grow its membership across the entire healthcare sector through 2023 and beyond.
The Endocrine Society has partnered with the Primary Aldosteronism Foundation in the past via the Hormone Health Network.
In 2016, the Endocrine Society released a Clinical Practice Guideline on the management of primary aldosteronism, which was featured in an issue of Endocrine News.